This special type of breast cancer is distinct from other ER-positive/HER2-negative form of breast cance in terms of the tumorigenicity of mutated genes, suggesting that the genomic profiling of unusual variants of breast cancer should be taken into account in developing suitable personalized management for patients [5]. This evidence concerns the gene ESR1 and breast cancer.